Affinity Asset Advisors’s Mereo BioPharma MREO Stock Holding History

Affinity Asset Advisors’s Portfolio MREO Stock Details MREO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-650,000	Closed	-$1.57M	–	67
2021 Q3	$1.57M	Hold	650,000	–	–	0.4%	48
2021 Q2	$2.06M	Sell	650,000 -250,000	-28%	-$839K	0.74%	33
2021 Q1	$3.03M	Buy	900,000 +275,000	+44%	+$972K	1.03%	24
2020 Q4	$2.24M	Buy	+625,000	New	+$1.57M	1.19%	24

Other funds holding MREO

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Affinity Asset Advisors's MREO Position: Q4 2021 in Review

Affinity Asset Advisors sold out of Mereo BioPharma (MREO) in Q4 2021, closing a stake of 650,000 shares — an estimated $1.57M sold.

Affinity Asset Advisors first reported a position in MREO in Q4 2020 and held it in 4 quarters. The position peaked at $3.03M in Q1 2021. 72 funds tracked by Wall St. Rank hold MREO as of Q4 2021.

Affinity Asset Advisors reported no remaining Mereo BioPharma position as of Q4 2021 after selling out during the quarter.
Affinity Asset Advisors sold 650,000 Mereo BioPharma shares in Q4 2021, an estimated $1.57M.
Affinity Asset Advisors first reported a position in Mereo BioPharma in Q4 2020 and held it in 4 quarters.
Affinity Asset Advisors's Mereo BioPharma position peaked at $3.03M in Q1 2021.
72 funds tracked by Wall St. Rank held Mereo BioPharma as of Q4 2021.

Based on Affinity Asset Advisors's 13F filing for Q4 2021, filed 11 Feb 2022.